189 related articles for article (PubMed ID: 12851689)
1. Thymidine and hypoxanthine protection patterns of the folic acid-enhanced synergies for combinations of trimetrexate plus a polyglutamylatable inhibitor of purine or thymidylate synthesis against human ileocecal HCT-8 cells.
Faessel HM; Slocum HK; Rustum YM; Greco WR
Int J Oncol; 2003 Aug; 23(2):401-9. PubMed ID: 12851689
[TBL] [Abstract][Full Text] [Related]
2. Folic acid-enhanced synergy for the combination of trimetrexate plus the glycinamide ribonucleotide formyltransferase inhibitor 4-[2-(2-amino-4-oxo-4,6,7,8-tetrahydro-3H-pyrimidino[5,4,6][1,4]thiazin -6-yl)-(S)-ethyl]-2,5-thienoylamino-L-glutamic acid (AG2034): comparison across sensitive and resistant human tumor cell lines.
Faessel HM; Slocum HK; Rustum YM; Greco WR
Biochem Pharmacol; 1999 Mar; 57(5):567-77. PubMed ID: 9952321
[TBL] [Abstract][Full Text] [Related]
3. Super in vitro synergy between inhibitors of dihydrofolate reductase and inhibitors of other folate-requiring enzymes: the critical role of polyglutamylation.
Faessel HM; Slocum HK; Jackson RC; Boritzki TJ; Rustum YM; Nair MG; Greco WR
Cancer Res; 1998 Jul; 58(14):3036-50. PubMed ID: 9679969
[TBL] [Abstract][Full Text] [Related]
4. Biochemical and biological studies on 2-desamino-2-methylaminopterin, an antifolate the polyglutamates of which are more potent than the monoglutamate against three key enzymes of folate metabolism.
Rosowsky A; Galivan J; Beardsley GP; Bader H; O'Connor BM; Russello O; Moroson BA; DeYarman MT; Kerwar SS; Freisheim JH
Cancer Res; 1992 Apr; 52(8):2148-55. PubMed ID: 1313737
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxicity of antifolate inhibitors of thymidylate and purine synthesis to WiDr colonic carcinoma cells.
Smith SG; Lehman NL; Moran RG
Cancer Res; 1993 Dec; 53(23):5697-706. PubMed ID: 8242626
[TBL] [Abstract][Full Text] [Related]
6. The depletion of cellular ATP by AG2034 mediates cell death or cytostasis in a hypoxanthine-dependent manner in human prostate cancer cells.
Obajimi O; Melera PW
Cancer Chemother Pharmacol; 2008 Jul; 62(2):215-26. PubMed ID: 17896107
[TBL] [Abstract][Full Text] [Related]
7. Preclinical cellular pharmacology of LY231514 (MTA): a comparison with methotrexate, LY309887 and raltitrexed for their effects on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells.
Chen VJ; Bewley JR; Andis SL; Schultz RM; Iversen PW; Shih C; Mendelsohn LG; Seitz DE; Tonkinson JL
Br J Cancer; 1998; 78 Suppl 3(Suppl 3):27-34. PubMed ID: 9717988
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic and pharmacodynamic evaluation of the glycinamide ribonucleotide formyltransferase inhibitor AG2034.
McLeod HL; Cassidy J; Powrie RH; Priest DG; Zorbas MA; Synold TW; Shibata S; Spicer D; Bissett D; Pithavala YK; Collier MA; Paradiso LJ; Roberts JD
Clin Cancer Res; 2000 Jul; 6(7):2677-84. PubMed ID: 10914709
[TBL] [Abstract][Full Text] [Related]
9. Antifolate drug interactions: enhancement of growth inhibition due to the antipurine 5,10-dideazatetrahydrofolic acid by the lipophilic dihydrofolate reductase inhibitors metoprine and trimetrexate.
Galivan J; Nimec Z; Rhee M; Boschelli D; Oronsky AL; Kerwar SS
Cancer Res; 1988 May; 48(9):2421-5. PubMed ID: 2965613
[TBL] [Abstract][Full Text] [Related]
10. An inhibitor of glycinamide ribonucleotide formyltransferase is selectively cytotoxic to cells that lack a functional G1 checkpoint.
Zhang CC; Boritzki TJ; Jackson RC
Cancer Chemother Pharmacol; 1998; 41(3):223-8. PubMed ID: 9443639
[TBL] [Abstract][Full Text] [Related]
11. Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs.
Schultz RM; Chen VJ; Bewley JR; Roberts EF; Shih C; Dempsey JA
Semin Oncol; 1999 Apr; 26(2 Suppl 6):68-73. PubMed ID: 10598558
[TBL] [Abstract][Full Text] [Related]
12. Quantitation of folic acid enhancement of antifolate synergism.
Gaumont Y; Kisliuk RL; Parsons JC; Greco WR
Cancer Res; 1992 Apr; 52(8):2228-35. PubMed ID: 1532766
[TBL] [Abstract][Full Text] [Related]
13. Prevention of thymidine and hypoxanthine rescue from MTA (LY231514) growth inhibition by dipyridamole in human lung cancer cell lines.
Smith PG; Marshman E; Calvert AH; Newell DR; Curtin NJ
Semin Oncol; 1999 Apr; 26(2 Suppl 6):63-7. PubMed ID: 10598557
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of resistance to N-[5-[N-(3,4-dihydro-2-methyl-4- oxoquinazolin-6-ylmethyl)-N-methylamino]-2-thenoyl]-L-glutamic acid (ZD1694), a folate-based thymidylate synthase inhibitor, in the HCT-8 human ileocecal adenocarcinoma cell line.
Lu K; Yin MB; McGuire JJ; Bonmassar E; Rustum YM
Biochem Pharmacol; 1995 Jul; 50(3):391-8. PubMed ID: 7646540
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of de novo purine synthesis in human prostate cells results in ATP depletion, AMPK activation and induces senescence.
Obajimi O; Keen JC; Melera PW
Prostate; 2009 Aug; 69(11):1206-21. PubMed ID: 19434633
[TBL] [Abstract][Full Text] [Related]
16. AG2034: a novel inhibitor of glycinamide ribonucleotide formyltransferase.
Boritzki TJ; Barlett CA; Zhang C; Howland EF
Invest New Drugs; 1996; 14(3):295-303. PubMed ID: 8958185
[TBL] [Abstract][Full Text] [Related]
17. Modulation of both endogenous folates and thymidine enhance the therapeutic efficacy of thymidylate synthase inhibitors.
van der Wilt CL; Backus HH; Smid K; Comijn L; Veerman G; Wouters D; Voorn DA; Priest DG; Bunni MA; Mitchell F; Jackman AL; Jansen G; Peters GJ
Cancer Res; 2001 May; 61(9):3675-81. PubMed ID: 11325838
[TBL] [Abstract][Full Text] [Related]
18. Biochemical studies on PT523, a potent nonpolyglutamatable antifolate, in cultured cells.
Rhee MS; Galivan J; Wright JE; Rosowsky A
Mol Pharmacol; 1994 Apr; 45(4):783-91. PubMed ID: 7514264
[TBL] [Abstract][Full Text] [Related]
19. N10-propargyl-5,8-dideazafolic acid (CB3717): inhibitory effects on human leukemia cell lines resistant to methotrexate or trimetrexate.
Takemura Y; Ohnuma T
Mt Sinai J Med; 1992 Oct; 59(5):419-24. PubMed ID: 1435841
[TBL] [Abstract][Full Text] [Related]
20. Loss of reduced folate carrier function and folate depletion result in enhanced pemetrexed inhibition of purine synthesis.
Zhao R; Zhang S; Hanscom M; Chattopadhyay S; Goldman ID
Clin Cancer Res; 2005 Feb; 11(3):1294-301. PubMed ID: 15709201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
